U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049133) titled 'Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer' on June 25.
Brief Summary: the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD)
The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities
Study Start Date: Jul...